Drug Profile
DLBS 3233
Alternative Names: DLBS-3233; InlacinLatest Information Update: 04 Jun 2019
Price :
$50
*
At a glance
- Originator Dexa Medica
- Class Antihyperglycaemics; Thiazolidinediones
- Mechanism of Action Adiponectin stimulants; GLUT4 stimulants; Lipoprotein modulators; Peroxisome proliferator-activated receptor gamma modulators; Phosphatidylinositol 3 kinase alpha modulators; Proto oncogene protein c akt modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Type 2 diabetes mellitus
- Phase III Polycystic ovary syndrome
Most Recent Events
- 31 May 2019 Dexa Medica Group completes the phase III POSITIF trial in Polycystic ovary syndrome in Indonesia (PO) (NCT01999686)
- 01 Apr 2018 Dexa Medica completes a phase III trial for Polycystic ovary syndrome in Indonesia (NCT01733459)
- 11 Jun 2015 No recent reports of development identified - Phase-III for Type-2 diabetes mellitus (Prevention) in Indonesia (PO)